501LBA LBA Orals: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
癌症
医学
肺癌
肿瘤科
内科学
作者
Benjamin Herzberg,Melissa L. Johnson,Chun‐Gon Kim,A. W. Tolcher,J. Rodon,Charlene Mantia,J. Liu,A. Tripathi,Luis Paz-Ares Rodríguez,Thibault De La Motte Rouge,C.M. Choi,Jiajun Han,Long Kwei,E. Liu,Sachdev Jc,Michael O'Quigley,Mark White,Darrin M. Beaupre,H.R. Kim